Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vixarelimab in moderate to severe ulcerative colitis
NCT06137183Phase 2Terminated
- Sponsor
- Genentech
- Start
- May 2024
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of vixarelimab in ulcerative colitis (UC), sponsored by Genentech. Started May 2024; status: terminated.
02
Drugs
vixarelimab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06137183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06137183.